Latanoprost - Model FA SR - Ocular Implant

Being developed to reduce IOP caused by Open-Angle Glaucoma & Ocular Hypertension. Clinical Investigation Stage: Phase II.

Most popular related searches

ocular implants

ocular implant

Micro implant. Sustained drug release.

The Target Product Profile for the Latanoprost FA SR Ocular Implant, currently under development, aims to deliver the following clinical benefits:

PolyActiva achieved study objectives in completed clinical study (NCT03604328) and interim analysis of ongoing study NCT04060758. The Latanoprost FA SR Ocular implant has not been approved by the U.S. Food and Drug Administration (FDA).

Latanoprost - Model FA SR - Ocular Implant

Benefits